Table 1.
Cases | Age | Sex | FT3 (pmol/L) (3.1–6.8) | FT4 (pmol/L) (12–22) | TSH (miU/L) (0.27–4.2) | CRP (mg/L) (0–5) | ESR (mm/h) (0–20) | ∗Tc 99m /RAI Uptake (%) (0.3–3 vs. 20–50) | Ultrasonography |
---|---|---|---|---|---|---|---|---|---|
1 | 42 | F | NA | 19.9 | 0.2 | NA | 55 | Low/0.2 | 3.2 cm hypoechoic nodule |
2 | 56 | F | 6.73 | 26.3 | 0.009 | NA | 34 | 0.06/1.35 | Diffuse HEAs, 2.2 cm hypo-isoechoic nodule |
3 | 56 | F | 4.5 | 21.1 | 0.68 | 125.0 | 100 | 0.59/NA focal hypoactivity | 1.8 cm focal HEA, 0.7 cm hypoechoic nodule with microcalcification |
4 | 51 | M | NA | 44.2 | 0.01 | NA | 91 | Low/NA | Focal HEAs, 1.6 cm isoechoic nodule |
5 | 52 | F | 7.01 | 24.7 | 0.02 | 15.6 | 60 | Low/NA | 2.4 cm heterogenous nodule with calcification and 1.1 cm isoechoic nodule |
6 | 45 | F | 13 | 45 | 0.005 | 138.8 | 132 | Low/NA | 2.2 cm hypoechoic, 1.9 cm isoechoic nodules |
CRP =C-reactive protein; ESR = erythrocyte sedimentation rate; F = female; FT3 = free triiodothyronine; FT4 = free thyroxine; HEA = hypoechogenic area; M = male; NA, not available; RAI = radioactive iodine; Tc 99m = Technetium-99m; TSH = thyroid-stimulating hormone
All of the patients had Technetium-99m scintigraphy, additionally some of them had either Technetium-99m uptake or 24-h RAI uptake.